BR112014010693A2 - uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes - Google Patents

uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes Download PDF

Info

Publication number
BR112014010693A2
BR112014010693A2 BR112014010693-2A BR112014010693A BR112014010693A2 BR 112014010693 A2 BR112014010693 A2 BR 112014010693A2 BR 112014010693 A BR112014010693 A BR 112014010693A BR 112014010693 A2 BR112014010693 A2 BR 112014010693A2
Authority
BR
Brazil
Prior art keywords
compound
gout
use according
individual
uric acid
Prior art date
Application number
BR112014010693-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Gopal Chandra Saha
Brian K. Roberts
Brian Edward Lavan
Charles A. McWherter
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of BR112014010693A2 publication Critical patent/BR112014010693A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014010693-2A 2011-11-04 2011-11-04 uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes BR112014010693A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (1)

Publication Number Publication Date
BR112014010693A2 true BR112014010693A2 (pt) 2020-11-10

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010693-2A BR112014010693A2 (pt) 2011-11-04 2011-11-04 uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes

Country Status (14)

Country Link
EP (1) EP2775835A4 (cg-RX-API-DMAC7.html)
JP (1) JP6047172B2 (cg-RX-API-DMAC7.html)
KR (1) KR101848122B1 (cg-RX-API-DMAC7.html)
CN (1) CN104066323A (cg-RX-API-DMAC7.html)
AU (1) AU2011380509B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010693A2 (cg-RX-API-DMAC7.html)
CA (1) CA2859689C (cg-RX-API-DMAC7.html)
CL (1) CL2014001156A1 (cg-RX-API-DMAC7.html)
IL (1) IL232385A (cg-RX-API-DMAC7.html)
MX (1) MX354846B (cg-RX-API-DMAC7.html)
NZ (1) NZ624714A (cg-RX-API-DMAC7.html)
SG (1) SG11201402027PA (cg-RX-API-DMAC7.html)
WO (1) WO2013066352A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403574B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013245675B2 (en) * 2012-04-13 2017-02-09 Cymabay Therapeutics, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
CN106036135A (zh) * 2014-07-25 2016-10-26 许伟琦 一种防止结石、快速排结石的药物、组合物、兽药
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
JP7086980B2 (ja) * 2017-10-26 2022-06-20 大塚製薬株式会社 イノシトールリン酸含有組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
BRPI0819847B1 (pt) * 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições

Also Published As

Publication number Publication date
ZA201403574B (en) 2015-11-25
SG11201402027PA (en) 2014-09-26
CN104066323A (zh) 2014-09-24
KR101848122B1 (ko) 2018-04-11
EP2775835A4 (en) 2015-07-29
MX354846B (es) 2018-03-22
IL232385A0 (en) 2014-06-30
CL2014001156A1 (es) 2015-01-16
WO2013066352A1 (en) 2013-05-10
CA2859689C (en) 2018-05-22
JP6047172B2 (ja) 2016-12-21
CA2859689A1 (en) 2013-05-10
AU2011380509B2 (en) 2016-05-19
JP2014532759A (ja) 2014-12-08
IL232385A (en) 2017-10-31
AU2011380509A1 (en) 2014-05-29
NZ624714A (en) 2016-01-29
KR20140123927A (ko) 2014-10-23
EP2775835A1 (en) 2014-09-17
MX2014005399A (es) 2015-04-08

Similar Documents

Publication Publication Date Title
AU2011380510B2 (en) Methods for treating gout flares
AU2011380507B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
AU2011380509B2 (en) Methods for treating gout in patient subpopulations
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法
Malice et al. Montelukast for treating seasonal allergic rhinitis: Effect of pollen counts in 3 fall studies

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]